Human endotoxemia: A model for mechanistic insight and therapeutic targeting

Shock

Volumn 24, Issue SUPPL. 1, 2005, Pages 94-100

  Lowry, Stephen F ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Biologic response modifiers; Endotoxemia; Humans

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER;

BIOCHEMISTRY; BLOOD CLOTTING DISORDER; CARDIOVASCULAR FUNCTION; CIRCULATION; CLINICAL FEATURE; COMORBIDITY; DISEASE MARKER; ENDOTOXEMIA; ENVIRONMENTAL FACTOR; GENETICS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFECTION; INFLAMMATION; INJURY; LUNG FUNCTION; METABOLISM; MODEL; MOLECULAR BIOLOGY; NEUROENDOCRINOLOGY; NORMAL HUMAN; NUTRITIONAL STATUS; PATHOGENESIS; PHENOTYPIC VARIATION; PHYSICAL CHEMISTRY; RESUSCITATION; REVIEW; THERAPEUTIC TARGETING; THERAPY; TREATMENT RESPONSE;

ENDOTOXEMIA; ENDOTOXINS; HUMAN EXPERIMENTATION; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS; TIME FACTORS;

EID: 33646817775     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000191340.23907.a1     Document Type: Review

References (73)

1. Hochstein HD, Mills DF, Outschoorn AS, Rastogi SC: The processing and collaborative assay of reference endotoxin. J Biol Stand 11:251-260, 1983.
2. Poole S, Dawson P, Gaines Das RE: Second international standard for endotoxin: calibration in an international collaborative study. J Endotoxin Res 4:221-231, 1997.
3. De Winter RJ, von der Möhlen MAM, van Lieshout H, Wedel N, Nelson B, Friedmann N, Delemarre BJ, van Deventer SJ: Recombinant endotoxin-binding protein (rBPI123) attenuates endotoxin-induced circulatory changes in humans. J Inflamm 45:193-206, 1995.
4. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parillo JE: Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. Am Rev Respir Dis 145:1398-1403, 1992.
5. Smith PD, Suffredini AF, Allen JB, Wahl LM, Parillo JE, Wahl SM: Endotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators. J Clin Immunol 14:141-148, 1994.
6. Van Zee KJ, Kohno T, Fischer E, Rock SC, Moldawer LL, Lowry SF: Tumor necrosis factor-soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992.
7. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, Moldawer LL, Lowry SF: Glucocorticoid therapy alters hormonal and cytokine responses of endotoxin in man. J Immunol 150:1999-2006, 1993.
8. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HS, Stiles DM, Pribble J, Catalano M, Moldawer LL, Lowry SF: Influence of interleukin-1 receptor blockade on the human response to endotoxemia. J Immunol 154:1499-1507, 1995.
9. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA: Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151:1637-1645, 1993.
10. Van der Poll T, Coyle SM, Moldawer LL, Lowry SF: Changes in endotoxin-induced cytokine production by whole blood after in vivo exposure of normal humans to endotoxin. J Infect Dis 174:1356-1360, 1996.
11. Kimmings AN, Pajkrt D, Zaaijer K: Factors involved in early in vitro endotoxin hyporesponsiveness in human endotoxemia. J Endotoxin Res 3:283-289, 1996.
12. Rogy MA, Oldenburg HS, Coyle S, Trousdale R, Moldawer LL, Lowry SF: Correlation between acute physiology and chronic health evaluation (APACHE) III score and immunological parameters in critically ill patients with sepsis. Br J Surg 83:396-400, 1996.
13. Fong Y, Moldawer LL, Marano M, Wei H, Tatter SB, Clarick R, Santhanam U, Sherris D, May LT, Sehgal PB, Lowry SF: Endotoxemia elicits increased circulating β2-IFN/IL-6 in man. J Immunol 142:2321-2324, 1989.
14. Van Zee KJ, DeForge LE, Fischer E, Marano MA, Kenney JS, Remick DG, Lowry SF, Moldawer LL: IL-8 in septic shock, endotoxemia and after IL-1 administration. J Immunol 146:3478-3482, 1991.
15. Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of anti-inflammatory agents. J Exp Med 173:1021-1024, 1991.
16. Sylvester I, Suffredini AF, Boujoukos AJ, Martich GD, Danner RL, Yoshimura T, Leonard EJ: Neutrophil attractant protein-1 and monocytes chemoattractant protein-1 in human serum. J Immunol 151:3292-3298, 1993.
17. Mackensen A, Galanos C, Engelhardt R: Modulating activity of interferon-γ on endotoxin-induced cytokine production in cancer patients. Blood 78:3254-3258, 1991.
18. Pajkrt D, Manten A, van der Poll T, Tiel-van Buul MM, Jansen J, Wouter ten Cate J, van Deventer SJ: Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 90:1415-1424, 1997.
19. Grobmyer SR, Lin E, Lowry SF, Rivadeneira DE, Potter S, Barie PS, Nathan CF: Elevation of IL-18 in human sepsis. J Clin Immunol 20:212-215, 2000.
20. Preas HL II, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, Suffredini AF: Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 88:2465-2472, 1996.
21. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor-soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992.
22. Fong Y, Matthews DE, He W, Marano M, Moldawer LL, Lowry SF: Whole body and splanchnic leucine, phenylalanine, and glucose kinetics during endotoxemia in man. Am J Physiol 266:R419-R425, 1994.
23. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA: Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 338:1423-1424, 1991.
24. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, Poutsiaka DD, Dinarello CA, Lowry SF, Moldawer LL: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196-2200, 1992.
25. Van der Poll T, de Waal MR, Coyle SM, Lowry SF: Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma-soluble interleukin (IL)-1 receptor type II, IL-10 and IL-13 concentrations. J Infect Dis 175:118-122, 1997.
26. Richardson RP, Rhyne CD, Fong Y, Hesse DG, Tracey KJ, Marano MA, Lowry SF, Antonacci AC, Calvano SE: Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects: influence of elicited hormones and cytokines. Ann Surg 210:239-245, 1989.
27. van der Poll T, Calvano SE, Kumar A, Braxton CC, Coyle SM, Barbosa K, Moldawer LL, Lowry SF: Endotoxin induces down-regulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 86:2754-2759, 1995.
28. Lin E, Katz JA, Calvano SE, Coyle SM, Randhawa S, Shahin I, Kumar A, Lowry SF: The influence of human endotoxemia upon CD95-induced apoptosis. Arch Surg 133:1322-1327, 1998.
29. Calvano JE, Agnese DM, Um JY, Goshima M, Singhal R, Coyle SM, Reddell MT, Kumar A, Calvano SE, Lowry SF: Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, and MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: relationship to tolerance. Shock 20:415-419, 2003.
30. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, Escol G, Jilma B, Key NS: Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 103:4545-4553, 2004.
31. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76:2520-2526, 1990.
32. Suffredini AF, Harpel PC, Parrillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165-1172, 1989.
33. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038-5045, 1995.
34. Godin PJ, Fleisher LA, Eidsath A, Vandivier RW, Preas HL, Banks SM, Buchman TG, Suffredini AF: Experimental human endotoxemia increases cardiac regularity: results from a prospective, randomized, crossover trial. Crit Care Med 24:1117-1124, 1996.
35. Winchell RJ, Hoyt DB: Analysis of heart-rate variability: a noninvasive predictor of death and poor outcome in patients with severe head injury. J Trauma 43:927-933, 1997.
36. O'Grady NP, Preas HL, Pugin J, Fiuza C, Propea M, Reda D, Banks SM, Suffredini AF: Local inflammatory responses following bronchial endotoxin installation in humans. Am J Respir Crit Care Med 163:1591-1598, 2001.
37. Thorn J: The inflammatory response in humans after inhalation of bacterial endotoxin: a review. Inflamm Res 50:254-261, 2001.
38. O'Dwyer ST, Michie HR, Ziegler TR, Revhaug A, Smith RJ, Wilmore DW: A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg 123:1459-1464, 1988.
39. Fong YM, Marano MA, Barber A, He W, Moldawer LL, Bushman ED, Coyle SM, Shires GT, Lowry SF: Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg 210:449-456, 1989.
40. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF: The acute Splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85: 1896-1904, 1990.
41. Michie HR, Spriggs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, Arthur K, Dinarello CA, Cerami A, Wolff SM, Kufe DW, Wilmer DW: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280-286, 1988.
42. Lang CH, Pollard V, Fan J, Traber LD, Traber DL, Frost RA, Gelato MC, Prough DS: Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. Am J Physiol 273:R371-R378, 1997.
43. van der Poll T, Van Zee KJ, Endert E, Coyle SM, Stiles DM, Pribble JP, Catalano MA, Moldawer LL, Lowry SF: Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 80:1341-1346, 1995.
44. van der Poll T, Endert E, Coyle SM, Agosti JM, Lowry SF: Neutralization of tumor necrosis factor does not influence endotoxin-induced changes in thyroid hormone metabolism in man. Am J Physiol 276:R357-R362, 1999.
45. Braxton CC, Coyle S, Montegut W, van der Poll T, Roth M, Calvano S, Lowry SF: Parenteral nutrition alters monocyte TNF receptor activity. J Surg Res 59:23-28, 1995.
46. 2 assessed by a cyclooxygenase inhibitor. J Clin Endocrinol Metab 77:1156-1163, 1993.
47. Pollmächer T, Mullington J, Korth C, Schreiber W, Hermann D, Orth A, Galanos C, Holsboer F: Diurnal variations in the human host response to endotoxin. J Infect Dis 174:1040-1045, 1996.
48. Barber AE, Coyle SM, Fischer E, Smith C, van der Poll T, Shires GT, Lowry SF: Influence of hypercortisolemia on soluble TNF receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 118:406-411, 1995.
49. van der Poll T, Barber AE, Coyle SM, Lowry SF: Hypercortisolemia increases plasma interleukin 10 concentrations during human endotoxemia. J Clin Endocrinol Metab 81:3604-3606, 1996.
50. Lin E, Calvano SE, Coyle S, Rumalla V, Kumar A, Lowry SF: Physiologic hypercortisolemia in humans modulates neutrophil CD95-signal transduction. Surg Forum 50:288-290, 1999.
51. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713-719, 1996.
52. van der Poll T, Levi M, Dentener M, Jansen PM, Coyle SM, Braxton CC, Buurman WA, Hack CE, ten Cate JW, Lowry SF: Epinephrine exerts anticoagulant effects during human endotoxemia. J Exp Med 185:1143-1148, 1997.
53. van der Poll T, Levi M, Braxton CC, Coyle SM, Roth M, ten Cate JW, Lowry SF: Parenteral nutrition facilitates activation of coagulation, but not of fibrinolysis, during human endotoxemia. J Infect Dis 177:793-795, 1998.
54. van der Poll T, Coyle SM, Levi M, Boermeester MA, Braxton CC, Jansen PM, Hack CE, Lowry SF: Fat emulsion infusion potentiates coagulation activation during human endotoxemia. Thromb Haemost 75:83-86, 1996.
55. Calvano JE, Coyle SM, Goshima M, Kumar A, Reddell MT, Um JY, Corbett SA, Calvano SE, Lowry SF: Response to IV lipopolysaccharide (LPS) in normal human subjects: effect of mutations in the human toll-like receptor 4 (hTRL4) gene. J Am Coll Surg 197:S33, 2003.
56. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry SF: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186:1522-1525, 2002.
57. Lin E, Coyle SM, Randhawa S, Shahin IS, Kumar A, Meligeni J, Robbins B, Calvano SE, Lowry SF: PMX-622 prevents endotoxin-induced inflammation in humans. Surg Forum 49:6-8, 1998.
58. von der Möhlen MA, van Deventer SJ, Levi M, van den Ende B, Wedel NI, Nelson BJ, Friedmann N, ten Cate JW: Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBP123). Blood 85:3437-3443, 1995.
59. von der Möhlen MA, Kimmings AN, Wedel NI, Mevissen ML, Jansen J, Friedmann N, Lorenz TJ, Nelson BJ, White ML, Bauer R: Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 172:144-151, 1995.
60. Pajkrt D, Lerch PG, van der Poll T, Levi M, Ill M, Doran JE, Arnet B, van den Ende A, ten Cate JW, van Deventer SJ: Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost 77:303-307, 1997.
61. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ: Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184:1601-1608, 1996.
62. Santos AA, Scheltinga MR, Lynch E, Brown EF, Lawton P, Chambers E, Browning J, Dinarello CA, Wolff SM, Wilmore DW: Elaboration of interleukin-1 receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 128:138-144, 1993.
63. Pajkrt D, Camoglio L, Tiel-van Buul MC, de Bruin K, Cutler DL, Affrime MB, Rikken G, van der Poll T, ten Cate JW, van Deventer SJ: Attentuation of proinflammatory response by recombinant human IL-10 in human endotoxemia; the effect of timing of rhIL-10 administration. J Immunol 158:3971-3977, 1997.
64. Pollmächrt T, Korth C, Mullington J: Effects of granulocyte colony-stimulating factor on plasma cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 87:900-905, 1996.
65. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481-1486, 1988.
66. Spinas GA, Bloesch D, Keller U, Zimmerli W, Cammisuli S: Pretreatment with ibuprofen augments circulating tumor necrosis factor-α, interleukin-6, and elastase during acute endotoxemia. J Infect Dis 163:89-95, 1991.
67. Zabel P, Wolter DT, Schönharting MM, Schade UF: Oxpentifylline in endotoxaemia. Lancet ii:1474-1477, 1989.
68. Branger J, Vanden Blink B, Weijer S, Madwen J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DB, Hack CE, Van-Deventer SJ, Peppelenbosch MP, van der Poll T: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168:4070-4077, 2002.
69. Derhaschnig U, Pemerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B: Evaluation of anti-inflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 31:1108-1112, 2003.
70. de Jonge E, Dekkers PEP, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJH, van der Poll T: Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 183: 1815-1818, 2001.
71. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B: Recombinant human activated protein C (rhAPC; drotecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 102:2093-2098, 2003.
72. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF: Effects of drotecogin alfa (activated) in human endotoxemia. Shock 21:222-229, 2004.
73. Calvano SE, Xiao W, Richards DR, Feliciano RM, Baker HV, Cho RJ, Chen RO, Brownslein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF: Inflammation and host response to injury large scale collaborative research program. A network-based analysis of systemic inflammation in humans. Nature 437:1032-1037, 2005.